Citations (120)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Leilei Ai, Ziheng Xu, Bo Yang, Qiaojun He & Peihua Luo. (2019) Sorafenib-associated hand-foot skin reaction: practical advice on diagnosis, mechanism, prevention, and management. Expert Review of Clinical Pharmacology 12:12, pages 1121-1127.
Read now
Read now
Gamze Guney Eskiler, Asuman Ozkan Deveci, Cemil Bilir & Suleyman Kaleli. (2019) Synergistic Effects of Nobiletin and Sorafenib Combination on Metastatic Prostate Cancer Cells. Nutrition and Cancer 71:8, pages 1299-1312.
Read now
Read now
Pulat Akιn Sabancι, Mine Ergüven, Nuray Yazihan, Esin Aktaş, Yavuz Aras, Erdinç Civelek, Aydιn Aydoseli, Murat İmer, Mehmet Gürtekin & Ayhan Bilir. (2014) Sorafenib and lithium chloride combination treatment shows promising synergistic effects in human glioblastoma multiforme cells in vitro but midkine is not implicated. Neurological Research 36:3, pages 189-197.
Read now
Read now
Nina Nandy & Constantin A Dasanu. (2013) Management of advanced and/or metastatic carcinoid tumors: historical perspectives and emerging therapies. Expert Opinion on Pharmacotherapy 14:12, pages 1649-1658.
Read now
Read now
Kwong-Fai Wong, Zhi Xu, Jinfei Chen, Nikki P Lee & John M Luk. (2013) Circulating markers for prognosis of hepatocellular carcinoma. Expert Opinion on Medical Diagnostics 7:4, pages 319-329.
Read now
Read now
Articles from other publishers (115)
Yanhua He, Zhendong Pan, Yan Liu, Liangliang Jiang, Haoran Peng, Ping Zhao, Zhongtian Qi, Yangang Liu & Hailin Tang. (2023) Identification of tyrphostin AG879 and A9 inhibiting replication of chikungunya virus by screening of a kinase inhibitor library. Virology 588, pages 109900.
Crossref
Crossref
Pengpeng Liu, Ping’an Ding, Chenyu Sun, Shuya Chen, Scott Lowe, Lingjiao Meng & Qun Zhao. (2023) Lymphangiogenesis in gastric cancer: function and mechanism. European Journal of Medical Research 28:1.
Crossref
Crossref
Xi Jin, Jingwei Zhao, Hongshuang Li, Mengting Zheng, Jiao Shao & Zhanguo Chen. (2023) Research trends and hot spots in global nanotechnology applications in liver cancer: a bibliometric and visual analysis (2000-2022). Frontiers in Oncology 13.
Crossref
Crossref
Paulina Śledzińska, Marek Bebyn, Jacek Furtak, Agnieszka Koper & Krzysztof Koper. (2023) Current and promising treatment strategies in glioma. Reviews in the Neurosciences 34:5, pages 483-516.
Crossref
Crossref
Qian Zhong, Xina Xiao, Yijie Qiu, Zhiqiang Xu, Chunyu Chen, Baochen Chong, Xinjun Zhao, Shan Hai, Shuangqing Li, Zhenmei An & Lunzhi Dai. (2023) Protein posttranslational modifications in health and diseases: Functions, regulatory mechanisms, and therapeutic implications. MedComm 4:3.
Crossref
Crossref
Raquel Gil-Edo, Santiago Royo, Miguel Carda & Eva Falomir. (2023) Unveiling the Potential of BenzylethyleneAryl–Urea Scaffolds for the Design of New Onco Immunomodulating Agents. Pharmaceuticals 16:6, pages 808.
Crossref
Crossref
Chiuyen Phan, Thi Trung Chinh Nguyen, Thi Van Thanh Do & Guping Tang. (2023) Preparation and characterization of sorafenib-loading microcapsules by complex coacervation of gum Arabic with chitosan or modified chitosan. Matéria (Rio de Janeiro) 28:1.
Crossref
Crossref
Rumela Mitra, M. Aswanth Harish & Bithiah Grace Jaganathan. 2023. Healthcare Research and Related Technologies. Healthcare Research and Related Technologies
119
131
.
Catherine Wegner Wippel, Hari Deshpande, Huned Patwa & Aldo J Peixoto. (2022) Neurogenic orthostatic hypotension after treatment with sorafenib. BMJ Case Reports 15:12, pages e247140.
Crossref
Crossref
Sameena Gul, Muhammad Faisal Maqbool, Amara Maryam, Muhammad Khan, Hafiz Abdullah Shakir, Muhammad Irfan, Chaman Ara, Yongming Li & Tonghui Ma. (2022) Vitamin K: A novel cancer chemosensitizer. Biotechnology and Applied Biochemistry 69:6, pages 2641-2657.
Crossref
Crossref
Suzan Abdu, Nouf Juaid, Amr Amin, Mohamed Moulay & Nabil Miled. (2022) Effects of Sorafenib and Quercetin Alone or in Combination in Treating Hepatocellular Carcinoma: In Vitro and In Vivo Approaches. Molecules 27:22, pages 8082.
Crossref
Crossref
Elisa Callegari, Paola Guerriero, Cristian Bassi, Lucilla D’Abundo, Antonio Frassoldati, Edi Simoni, Laura Astolfi, Enrico Maria Silini, Silvia Sabbioni & Massimo Negrini. (2022) miR-199a-3p increases the anti-tumor activity of palbociclib in liver cancer models. Molecular Therapy - Nucleic Acids 29, pages 538-549.
Crossref
Crossref
Miguel A. Zaballos, Adrián Acuña-Ruiz, Marta Morante, Garcilaso Riesco-Eizaguirre, Piero Crespo & Pilar Santisteban. (2022) Inhibiting ERK dimerization ameliorates BRAF-driven anaplastic thyroid cancer. Cellular and Molecular Life Sciences 79:9.
Crossref
Crossref
Ya-Ping Chan, Cheng-Hung Chuang, Inn Lee & Nae-Cherng Yang. (2022) Lycopene in Combination With Sorafenib Additively Inhibits Tumor Metastasis in Mice Xenografted With Lewis Lung Carcinoma Cells. Frontiers in Nutrition 9.
Crossref
Crossref
Timothy A. Dinh, Alan F. Utria, Kevin C. Barry, Rosanna Ma, Ghassan K. Abou-Alfa, John D. Gordan, Elizabeth M. Jaffee, John D. Scott, Jessica Zucman-Rossi, Allison F. O’Neill, Mark E. Furth & Praveen Sethupathy. (2022) A framework for fibrolamellar carcinoma research and clinical trials. Nature Reviews Gastroenterology & Hepatology 19:5, pages 328-342.
Crossref
Crossref
Arlinda Ljoki, Tanzila Aslam, Tina Friis, Ragnhild G. Ohm & Gunnar Houen. (2022) In Vitro Angiogenesis Inhibition and Endothelial Cell Growth and Morphology. International Journal of Molecular Sciences 23:8, pages 4277.
Crossref
Crossref
Seung Un Seo, Seon Min Woo, Seung-Soon Im, Younghoon Jang, Eugene Han, Sang Hyun Kim, Hongchan Lee, Hyun-Shik Lee, Ju-Ock Nam, Edward Gabrielson, Kyoung-jin Min & Taeg Kyu Kwon. (2022) Cathepsin D as a potential therapeutic target to enhance anticancer drug-induced apoptosis via RNF183-mediated destabilization of Bcl-xL in cancer cells. Cell Death & Disease 13:2.
Crossref
Crossref
Makhadumsab Toragall, Shridhar C. Ghagane, Rajendra B. Nerli & Murigendra B. Hiremath. 2022. Male Reproductive Anatomy. Male Reproductive Anatomy.
Emilie Logie, Claudina Perez Novo, Amber Driesen, Pieter Van Vlierberghe & Wim Vanden Berghe. (2021) Phosphocatalytic Kinome Activity Profiling of Apoptotic and Ferroptotic Agents in Multiple Myeloma Cells. International Journal of Molecular Sciences 22:23, pages 12731.
Crossref
Crossref
Meira Yisraeli Salman, Jacob M. Rowe & Nir Weigert. (2021) Inhibition of FLT3: A Prototype for Molecular Targeted Therapy in Acute Myeloid Leukemia. Engineering 7:10, pages 1354-1368.
Crossref
Crossref
F. Bagheri & M. H. Fatemi. (2021) Investigation of the Interaction of Sorafenib with Alpha-Lactalbumin: Spectroscopic and Molecular Modeling. Russian Journal of Bioorganic Chemistry 47:4, pages 864-873.
Crossref
Crossref
Chi Uyen Phan, Jie Shen, Kaxi Yu, Jianming Mao & Guping Tang. (2021) Impact of Crystal Habit on the Dissolution Rate and In Vivo Pharmacokinetics of Sorafenib Tosylate. Molecules 26:11, pages 3469.
Crossref
Crossref
Fan Pan, Xin-Rong Lin, Li-Ping Hao, Xiao-Yuan Chu, Hai-Jun Wan & Rui Wang. (2021) The Role of RNA Methyltransferase METTL3 in Hepatocellular Carcinoma: Results and Perspectives. Frontiers in Cell and Developmental Biology 9.
Crossref
Crossref
Wei Jiang, Tao Li, Jiaojiao Guo, Jingjing Wang, Lizhou Jia, Xiao shi, Tingting Yang, Ruonan Jiao, Xin Wei, Zhenqing Feng, Qi Tang & Guozhong Ji. (2021) Bispecific c-Met/PD-L1 CAR-T Cells Have Enhanced Therapeutic Effects on Hepatocellular Carcinoma. Frontiers in Oncology 11.
Crossref
Crossref
Raja David Isac Evangeline Breeta, Viswanathan Mariammal Berlin Grace & Devarajan David Wilson. (2020) Methyl Palmitate—A suitable adjuvant for Sorafenib therapy to reduce in vivo toxicity and to enhance anti‐cancer effects on hepatocellular carcinoma cells. Basic & Clinical Pharmacology & Toxicology 128:3, pages 366-378.
Crossref
Crossref
Alessia Catalano, Domenico Iacopetta, Maria Stefania Sinicropi & Carlo Franchini. (2021) Diarylureas as Antitumor Agents. Applied Sciences 11:1, pages 374.
Crossref
Crossref
Daniele Veclani, Marilena Tolazzi & Andrea Melchior. (2020) Molecular Interpretation of Pharmaceuticals’ Adsorption on Carbon Nanomaterials: Theory Meets Experiments. Processes 8:6, pages 642.
Crossref
Crossref
Nigel Fleeman, Rachel Houten, Adrian Bagust, Marty Richardson, Sophie Beale, Angela Boland, Yenal Dundar, Janette Greenhalgh, Juliet Hounsome, Rui Duarte & Aditya Shenoy. (2020) Lenvatinib and sorafenib for differentiated thyroid cancer after radioactive iodine: a systematic review and economic evaluation. Health Technology Assessment 24:2, pages 1-180.
Crossref
Crossref
Sreeja Dattachoudhury, Renu Sharma, Atul Kumar & Bithiah Grace Jaganathan. (2020) Sorafenib Inhibits Proliferation, Migration and Invasion of Breast Cancer Cells. Oncology 98:7, pages 478-486.
Crossref
Crossref
Jorge Hallak, Thiago Afonso Teixeira & Guilherme Leme de Souza. 2020. Male Infertility. Male Infertility
455
468
.
Xiaobo Li, Yong Li, Weijin Lu, Minfeng Chen, Wencai Ye & Dongmei Zhang. (2019) The Tumor Vessel Targeting Strategy: A Double-Edged Sword in Tumor Metastasis. Cells 8:12, pages 1602.
Crossref
Crossref
Chi Uyen Phan, Jie Shen, Jiyong Liu, Jianming Mao, Xiurong Hu & Guping Tang. (2019) Isomorphous Crystals Formed by the Similar Supramolecular Motifs in Sorafenib Hydrochloride and Regorafenib Hydrochloride Salts. Crystals 9:12, pages 649.
Crossref
Crossref
Chiuyen Phan, Ziyang Zheng, Jianwei Wang, Qiwen Wang, Xiurong Hu, Guping Tang & Hongzhen Bai. (2019) Enhanced antitumour effect for hepatocellular carcinoma in the advanced stage using a cyclodextrin-sorafenib-chaperoned inclusion complex. Biomaterials Science 7:11, pages 4758-4768.
Crossref
Crossref
K. C. Nicolaou & Stephan Rigol. (2019) The Role of Organic Synthesis in the Emergence and Development of Antibody–Drug Conjugates as Targeted Cancer Therapies. Angewandte Chemie International Edition 58:33, pages 11206-11241.
Crossref
Crossref
K. C. Nicolaou & Stephan Rigol. (2019) Die Bedeutung der organischen Synthese bei der Entstehung und Entwicklung von Antikörper‐Wirkstoff‐Konjugaten als gezielte Krebstherapien. Angewandte Chemie 131:33, pages 11326-11363.
Crossref
Crossref
Jun-Yan Liu. (2019) Inhibition of Soluble Epoxide Hydrolase for Renal Health. Frontiers in Pharmacology 9.
Crossref
Crossref
Abdul Hamid Bazarbachi, Rama Al Hamed, Florent Malard, Mohamad Mohty & Ali Bazarbachi. (2019)
Allogeneic transplant for
FLT3
-
ITD
mutated AML: a focus on
FLT3
inhibitors before, during, and after transplant
. Therapeutic Advances in Hematology 10, pages 204062071988266.
Crossref
Crossref
Yu Chen. Progress in research on protein tyrosine kinase inhibitors. Progress in research on protein tyrosine kinase inhibitors.
Giuseppina Novo, Daniela Di Lisi, Enrico Bronte, Manuela Fiuza & Fausto J. Pinto. 2019. Cardiovascular Complications in Cancer Therapy. Cardiovascular Complications in Cancer Therapy
33
44
.
Wagner Ricardo Montor, Andrei Ronaldo Oliveira Silva Escar Salas & Fabiana Henriques Machado de Melo. (2018) Receptor tyrosine kinases and downstream pathways as druggable targets for cancer treatment: the current arsenal of inhibitors. Molecular Cancer 17:1.
Crossref
Crossref
Flavia Storelli, Caroline Samer, Jean-Luc Reny, Jules Desmeules & Youssef Daali. (2018) Complex Drug–Drug–Gene–Disease Interactions Involving Cytochromes P450: Systematic Review of Published Case Reports and Clinical Perspectives. Clinical Pharmacokinetics 57:10, pages 1267-1293.
Crossref
Crossref
Amir Noeparast, Philippe Giron, Sylvia De Brakeleer, Carolien Eggermont, Ulrike De Ridder, Erik Teugels & Jacques De Grève. (2018) Type II RAF inhibitor causes superior ERK pathway suppression compared to type I RAF inhibitor in cells expressing different BRAF mutant types recurrently found in lung cancer. Oncotarget 9:22, pages 16110-16123.
Crossref
Crossref
Heinz Hammerlindl, Dinoop Ravindran Menon, Sabrina Hammerlindl, Abdullah Al Emran, Joachim Torrano, Katrin Sproesser, Divya Thakkar, Min Xiao, Victoria G. Atkinson, Brian Gabrielli, Nikolas K. Haass, Meenhard Herlyn, Clemens Krepler & Helmut Schaider. (2018)
Acetylsalicylic Acid Governs the Effect of Sorafenib in
RAS
-Mutant Cancers
. Clinical Cancer Research 24:5, pages 1090-1102.
Crossref
Crossref
Michael S. Samuel. 2018. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
4463
4468
.
Yanning Liu, Guohua Lou, John T. Norton, Chen Wang, Irawati Kandela, Shuai Tang, Nathaniel I. Shank, Pankaj Gupta, Min Huang, Michael J. Avram, Richard Green, Andrew Mazar, Daniel Appella, Zhi Chen & Sui Huang. (2017) 6‐Methoxyethylamino‐numonafide inhibits hepatocellular carcinoma xenograft growth as a single agent and in combination with sorafenib. The FASEB Journal 31:12, pages 5453-5465.
Crossref
Crossref
Shu-Xiong Zeng, Yanjun Zhu, Ai-Hong Ma, Weimin Yu, Hongyong Zhang, Tzu-Yin Lin, Wei Shi, Clifford G. Tepper, Paul T. Henderson, Susan Airhart, Jian-Ming Guo, Chuan-Liang Xu, Ralph W. deVere White & Chong-Xian Pan. (2017) The Phosphatidylinositol 3-Kinase Pathway as a Potential Therapeutic Target in Bladder Cancer. Clinical Cancer Research 23:21, pages 6580-6591.
Crossref
Crossref
Ahmed M. Al-Abd, Abdulmohsin J. Alamoudi, Ashraf B. Abdel-Naim, Thikryat A. Neamatallah & Osama M. Ashour. (2017) Anti-angiogenic agents for the treatment of solid tumors: Potential pathways, therapy and current strategies – A review. Journal of Advanced Research 8:6, pages 591-605.
Crossref
Crossref
M. Semet, M. Paci, J. Saïas-Magnan, C. Metzler-Guillemain, R. Boissier, H. Lejeune & J. Perrin. (2017) The impact of drugs on male fertility: a review. Andrology 5:4, pages 640-663.
Crossref
Crossref
Bernhard Gillissen, Anja Richter, Antje Richter, Robert Preissner, Klaus Schulze-Osthoff, Frank Essmann & Peter T. Daniel. (2017) Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma. Journal of Biological Chemistry 292:16, pages 6478-6492.
Crossref
Crossref
Daniela Di Lisi, Rosalinda Madonna, Concetta Zito, Enrico Bronte, Giuseppe Badalamenti, Paolo Parrella, Ines Monte, Carlo Gabriele Tocchetti, Antonio Russo & Giuseppina Novo. (2017) Anticancer therapy-induced vascular toxicity: VEGF inhibition and beyond. International Journal of Cardiology 227, pages 11-17.
Crossref
Crossref
Kellsye L. Fabian & Walter J. Storkus. 2017. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy. Tumor Immune Microenvironment in Cancer Progression and Cancer Therapy
191
211
.
D. Sikic, N. Meidenbauer, V. Lieb & B. Keck. (2016) Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der UrologieSide effect management of tyrosine kinase inhibitors in urology. Der Urologe 55:7, pages 952-955.
Crossref
Crossref
D. Sikic, G. Lüdecke, V. Lieb & B. Keck. (2016) Nebenwirkungsmanagement von Tyrosinkinaseinhibitoren in der UrologieSide effect management of tyrosine kinase inhibitors in urology. Der Urologe 55:5, pages 648-652.
Crossref
Crossref
Meng-yuan Li, Yong-cong Lv, Lin-jiang Tong, Ting Peng, Rong Qu, Tao Zhang, Yi-ming Sun, Yi Chen, Li-xin Wei, Mei-yu Geng, Wen-hu Duan, Hua Xie & Jian Ding. (2016) DW10075, a novel selective and small-molecule inhibitor of VEGFR, exhibits antitumor activities both in vitro and in vivo. Acta Pharmacologica Sinica 37:3, pages 398-407.
Crossref
Crossref
Kellsye L. Fabian & Walter J. Storkus. 2016. Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy. Defects in T Cell Trafficking and Resistance to Cancer Immunotherapy
51
76
.
Michael S. Samuel. 2016. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1
6
.
Y Liu, X Ye, J-B Zhang, H Ouyang, Z Shen, Y Wu, W Wang, J Wu, S Tao, X Yang, K Qiao, J Zhang, J Liu, Q Fu & Y Xie. (2015) PROX1 promotes hepatocellular carcinoma proliferation and sorafenib resistance by enhancing β-catenin expression and nuclear translocation. Oncogene 34:44, pages 5524-5535.
Crossref
Crossref
Ying Liu, Han Yue, Shuning Xu, Feng Wang, Ning Ma, Ke Li, Lei Qiao & Jufeng Wang. (2015) First-line gemcitabine and oxaliplatin (GEMOX) plus sorafenib, followed by sorafenib as maintenance therapy, for patients with advanced hepatocellular carcinoma: a preliminary study. International Journal of Clinical Oncology 20:5, pages 952-959.
Crossref
Crossref
Elizabeth A. Kuczynski, Christina R. Lee, Shan Man, Eric Chen & Robert S. Kerbel. (2015) Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. Cancer Research 75:12, pages 2510-2519.
Crossref
Crossref
Douglas A. Keller, Richard J. Brennan & Karen L. Leach. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
365
400
.
Mark C. Munson. 2015. Antitargets and Drug Safety. Antitargets and Drug Safety
329
364
.
Juan Pablo Rigalli, Nadia Ciriaci, Agostina Arias, María Paula Ceballos, Silvina Stella Maris Villanueva, Marcelo Gabriel Luquita, Aldo Domingo Mottino, Carolina Inés Ghanem, Viviana Alicia Catania & María Laura Ruiz. (2015) Regulation of Multidrug Resistance Proteins by Genistein in a Hepatocarcinoma Cell Line: Impact on Sorafenib Cytotoxicity. PLOS ONE 10:3, pages e0119502.
Crossref
Crossref
Rita Dornetshuber-Fleiss, Daniela Heilos, Thomas Mohr, Lennart Richter, Roderich D. Süssmuth, Markus Zlesak, Astrid Novicky, Petra Heffeter, Rosa Lemmens-Gruber & Walter Berger. (2015) The naturally born fusariotoxin enniatin B and sorafenib exert synergistic activity against cervical cancer in vitro and in vivo. Biochemical Pharmacology 93:3, pages 318-331.
Crossref
Crossref
L Bazzola, C Foroni, D Andreis, V Zanoni, M R Cappelletti, G Allevi, S Aguggini, C Strina, M Milani, S Venturini, F Ferrozzi, R Giardini, R Bertoni, H Turley, K Gatter, P G Petronini, S B Fox, A L Harris, M Martinotti, A Berruti, A Bottini, A R Reynolds & D Generali. (2014) Combination of letrozole, metronomic cyclophosphamide and sorafenib is well-tolerated and shows activity in patients with primary breast cancer. British Journal of Cancer 112:1, pages 52-60.
Crossref
Crossref
Djoeke de Wit, Henk-Jan Guchelaar, Jan den Hartigh, Hans Gelderblom & Nielka P. van Erp. (2015) Individualized dosing of tyrosine kinase inhibitors: are we there yet?. Drug Discovery Today 20:1, pages 18-36.
Crossref
Crossref
Theresa Stehmer & Stephen A. Bernard. 2015. Palliative Care in Oncology. Palliative Care in Oncology
157
185
.
EUN HO KIM, MI-SOOK KIM & WON-GYUN JUNG. (2014) The mechanisms responsible for the radiosensitizing effects of sorafenib on colon cancer cells. Oncology Reports 32:6, pages 2421-2128.
Crossref
Crossref
John G. Moffat, Joachim Rudolph & David Bailey. (2014) Phenotypic screening in cancer drug discovery — past, present and future. Nature Reviews Drug Discovery 13:8, pages 588-602.
Crossref
Crossref
Yi Gu, Jian Wang, Ke Li, Li Zhang, Hongcan Ren, Lixia Guo, Yang Sai, Weihan Zhang & Weiguo Su. (2014) Preclinical pharmacokinetics and disposition of a novel selective VEGFR inhibitor Fruquintinib (HMPL-013) and the prediction of its human pharmacokinetics. Cancer Chemotherapy and Pharmacology 74:1, pages 95-115.
Crossref
Crossref
Robert L. Cohen & Jeff Settleman. (2014) From Cancer Genomics to Precision Oncology—Tissue’s Still an Issue. Cell 157:7, pages 1509-1514.
Crossref
Crossref
Gwang Tae Noh, Mi-hyun Kim, Ji-Yeon Suh, Youngkyu Song, Chang Kyung Lee, Jin Hee Baek, Yong Seok Lee, Gyunggoo Cho, EunJu Kim, Young Ro Kim, Hyung Joon Cho, Dongyeol Lim & Jeong Kon Kim. (2013) Sunitinib–CLIO Conjugate: A VEGFR/PDGFR-Targeting Active MR Probe. Molecular Imaging and Biology 16:3, pages 340-349.
Crossref
Crossref
J.V. Gavilondo, F. Hernández-Bernal, M. Ayala-Ávila, A.V. de la Torre, J. de la Torre, Y. Morera-Díaz, M. Bequet-Romero, J. Sánchez, C.M. Valenzuela, Y. Martín, K.-H. Selman-Housein, A. Garabito & O.C. Lazo. (2014) Specific active immunotherapy with a VEGF vaccine in patients with advanced solid tumors. Results of the CENTAURO antigen dose escalation phase I clinical trial. Vaccine 32:19, pages 2241-2250.
Crossref
Crossref
G. Pittatore, A. Moggio BiolSci, C. Benedetto, B. Bussolati & A. Revelli. (2014) Endometrial Adult/Progenitor Stem Cells: Pathogenetic Theory and New Antiangiogenic Approach for Endometriosis Therapy. Reproductive Sciences 21:3, pages 296-304.
Crossref
Crossref
Vijaya R BhattApar Kishor Ganti. (2014) Sorafenib in squamous cell carcinoma of the head and neck: molecular basis and potential role. Future Oncology 10:1, pages 17-20.
Crossref
Crossref
Harina Vin, Grace Ching, Sandra S. Ojeda, Charles H. Adelmann, Vida Chitsazzadeh, David W. Dwyer, Haiching Ma, Karin Ehrenreiter, Manuela Baccarini, Rosamaria Ruggieri, Jonathan L. Curry, Ana M. Ciurea, Madeleine Duvic, Naifa L. Busaidy, Nizar M. Tannir & Kenneth Y. Tsai. (2014) Sorafenib Suppresses JNK-Dependent Apoptosis through Inhibition of ZAK. Molecular Cancer Therapeutics 13:1, pages 221-229.
Crossref
Crossref
Stephanie LankhorstMariëtte H.W. KappersJoep H.M. van EschA.H. Jan DanserAnton H. van den Meiracker. (2014) Hypertension During Vascular Endothelial Growth Factor Inhibition: Focus on Nitric Oxide, Endothelin-1, and Oxidative Stress. Antioxidants & Redox Signaling 20:1, pages 135-145.
Crossref
Crossref
Christina M. Annunziata & Phillip A. Dennis. 2014. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics. Handbook of Anticancer Pharmacokinetics and Pharmacodynamics
1
21
.
George R. BlumenscheinJrJr, Pierre Saintigny, Suyu Liu, Edward S. Kim, Anne S. Tsao, Roy S. Herbst, Christine Alden, J. Jack Lee, Ximing Tang, David J. Stewart, Merrill S. Kies, Frank V. Fossella, Hai T. Tran, L. Mao, Marshall E. Hicks, Jeremy ErasmusJrJr, Sanjay Gupta, Luc Girard, Michael Peyton, Lixia Diao, Jing Wang, Suzanne E. Davis, John D. Minna, Ignacio Wistuba, Waun K. Hong, John V. Heymach & Scott M. Lippman. (2013) Comprehensive Biomarker Analysis and Final Efficacy Results of Sorafenib in the BATTLE Trial. Clinical Cancer Research 19:24, pages 6967-6975.
Crossref
Crossref
Petra Heffeter, Bihter Atil, Kushtrim Kryeziu, Diana Groza, Gunda Koellensperger, Wilfried Körner, Ute Jungwirth, Thomas Mohr, Bernhard K. Keppler & Walter Berger. (2013) The ruthenium compound KP1339 potentiates the anticancer activity of sorafenib in vitro and in vivo. European Journal of Cancer 49:15, pages 3366-3375.
Crossref
Crossref
Hubert ServeUtz KrugRuth WagnerM. Cristina SauerlandAchim HeineckeUta BrunnbergMarkus SchaichOliver OttmannJustus DuysterHannes WandtThomas FischerAristoteles GiagounidisAndreas NeubauerAlbrecht ReichleWalter AulitzkyRichard NoppeneyIgor BlauVolker KunzmannReingard StuhlmannAlwin KrämerKarl-Anton KreuzerChristian BrandtsBjörn SteffenChristian ThiedeCarsten Müller-TidowGerhard EhningerWolfgang E. Berdel. (2013) Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial. Journal of Clinical Oncology 31:25, pages 3110-3118.
Crossref
Crossref
John R. Goffin & Kevin Zbuk. (2013) Epidermal Growth Factor Receptor: Pathway, Therapies, and Pipeline. Clinical Therapeutics 35:9, pages 1282-1303.
Crossref
Crossref
J Wan, T Liu, L Mei, J Li, K Gong, C Yu & W Li. (2013) Synergistic antitumour activity of sorafenib in combination with tetrandrine is mediated by reactive oxygen species (ROS)/Akt signaling. British Journal of Cancer 109:2, pages 342-350.
Crossref
Crossref
M. Majem & C. Pallarès. (2013) An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents. Clinical and Translational Oncology 15:5, pages 343-357.
Crossref
Crossref
David Chandler & Anthony Bewley. (2013) Biologics in Dermatology. Pharmaceuticals 6:4, pages 557-578.
Crossref
Crossref
JAE HO LEE, JAE WOONG SHIM, YOO JIN CHOI, KYU HEO & KWANGMO YANG. (2013) The combination of sorafenib and radiation preferentially inhibits breast cancer stem cells by suppressing HIF-1α expression. Oncology Reports 29:3, pages 917-924.
Crossref
Crossref
Stephanie Lankhorst, Mariëtte H.W. Kappers, Joep H.M. van Esch, A.H. Jan Danser & Anton H. van den Meiracker. (2013) Mechanism of hypertension and proteinuria during angiogenesis inhibition. Journal of Hypertension 31:3, pages 444-454.
Crossref
Crossref
Paola Rita Brunocilla, Franco Brunello, Patrizia Carucci, Silvia Gaia, Emanuela Rolle, Alessandro Cantamessa, Anna Castiglione, Giovannino Ciccone & Mario Rizzetto. (2012) Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Medical Oncology 30:1.
Crossref
Crossref
Ahad Eshraghian, Amir A'lam Kamyab & Seung Kew Yoon. (2013) Pharmacological Treatment for Hepatopulmonary Syndrome. BioMed Research International 2013, pages 1-10.
Crossref
Crossref
Aldo Moggio, Giulia Pittatore, Paola Cassoni, Gian Luigi Marchino, Alberto Revelli & Benedetta Bussolati. (2012) Sorafenib inhibits growth, migration, and angiogenic potential of ectopic endometrial mesenchymal stem cells derived from patients with endometriosis. Fertility and Sterility 98:6, pages 1521-1530.e2.
Crossref
Crossref
Anja Lachenmayer, Clara Alsinet, Radoslav Savic, Laia Cabellos, Sara Toffanin, Yujin Hoshida, Augusto Villanueva, Beatriz Minguez, Philippa Newell, Hung-Wen Tsai, Jordi Barretina, Swan Thung, Stephen C. Ward, Jordi Bruix, Vincenzo Mazzaferro, Myron Schwartz, Scott L. Friedman & Josep M. Llovet. (2012) Wnt-Pathway Activation in Two Molecular Classes of Hepatocellular Carcinoma and Experimental Modulation by Sorafenib. Clinical Cancer Research 18:18, pages 4997-5007.
Crossref
Crossref
Feng Wei, Yan Liu, Anita C. Bellail, Jeffrey J. Olson, Shi-Yong Sun, Guoyue Lu, Lijuan Ding, Changji Yuan, Guangyi Wang & Chunhai Hao. (2012) K-Ras mutation-mediated IGF-1-induced feedback ERK activation contributes to the rapalog resistance in pancreatic ductal adenocarcinomas. Cancer Letters 322:1, pages 58-69.
Crossref
Crossref
Andrea Weiss, Hubert van den Bergh, Arjan W. Griffioen & Patrycja Nowak-Sliwinska. (2012) Angiogenesis inhibition for the improvement of photodynamic therapy: The revival of a promising idea. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1826:1, pages 53-70.
Crossref
Crossref
Su Jin Lee, Jeeyun Lee, Se Hoon Park, Joon Oh Park, Young Suk Park, Won Ki Kang, Jongtae Lee, Dong-Seok Yim & Ho Yeong Lim. (2011) Phase 1 trial of S-1 in combination with sorafenib for patients with advanced hepatocellular carcinoma. Investigational New Drugs 30:4, pages 1540-1547.
Crossref
Crossref
Patrycja Nowak‐Sliwinska, Andrea Weiss, Judy R. van Beijnum, Tse J. Wong, Jean‐Pierre Ballini, Blaise Lovisa, Hubert van den Bergh & Arjan W. Griffioen. (2012) Angiostatic kinase inhibitors to sustain photodynamic angio‐occlusion. Journal of Cellular and Molecular Medicine 16:7, pages 1553-1562.
Crossref
Crossref
Atif A. Ahmed, Ashley K. Sherman & Bruce R. Pawel. (2012) Expression of therapeutic targets in Ewing sarcoma family tumors. Human Pathology 43:7, pages 1077-1083.
Crossref
Crossref
Antoine Italiano, Angela Cioffi, Paola Coco, Robert G. Maki, Patrick Schöffski, Piotr Rutkowski, Axel Le Cesne, Florence Duffaud, Antoine Adenis, Nicolas Isambert, Emmanuelle Bompas, Jean-Yves Blay, Paolo Casali, Mary Louise Keohan, Maud Toulmonde, Cristina R. Antonescu, Maria Debiec-Rychter, Jean-Michel Coindre & Binh Bui. (2011) Patterns of Care, Prognosis, and Survival in Patients with Metastatic Gastrointestinal Stromal Tumors (GIST) Refractory to First-Line Imatinib and Second-Line Sunitinib. Annals of Surgical Oncology 19:5, pages 1551-1559.
Crossref
Crossref
Roberto E Favoni, Antonio Daga, Paolo Malatesta & Tullio Florio. (2012) Preclinical studies identify novel targeted pharmacological strategies for treatment of human malignant pleural mesothelioma. British Journal of Pharmacology 166:2, pages 532-553.
Crossref
Crossref
Jorrit J. Hornberg. 2012. Designing Multi-Target Drugs. Designing Multi-Target Drugs
1
13
.
Melchiorre Cervello, James A. McCubrey, Antonella Cusimano, Nadia Lampiasi, Antonina Azzolina & Giuseppe Montalto. (2012) Targeted therapy for hepatocellular carcinoma: novel agents on the horizon. Oncotarget 3:3, pages 236-260.
Crossref
Crossref
Serap Gur, Philip J. Kadowitz & Wayne J.G. Hellstrom. (2012) Drugs of the future for Peyronie’s disease. Medical Hypotheses 78:2, pages 305-311.
Crossref
Crossref
Yafei Zhang, Bicheng Zhang, Anran Zhang, Yong Zhao, Jie Zhao, Jian Liu, Jianfei Gao, Dianchun Fang & Zhiguo Rao. (2012) Synergistic growth inhibition by sorafenib and vitamin K2 in human hepatocellular carcinoma cells. Clinics 67:9, pages 1093-1099.
Crossref
Crossref
Jessie-F. Fecteau, Ila S. Bharati, Morgan O’Hayre, Tracy M. Handel, Thomas J. Kipps & Davorka Messmer. (2011) Sorafenib-Induced Apoptosis of Chronic Lymphocytic Leukemia Cells Is Associated with Downregulation of RAF and Myeloid Cell Leukemia Sequence 1 (Mcl-1). Molecular Medicine 18:1, pages 19-28.
Crossref
Crossref
Katsuyuki Shirai, Michael R. Siedow & Arnab Chakravarti. (2012) Antiangiogenic Therapy for Patients with Recurrent and Newly Diagnosed Malignant Gliomas. Journal of Oncology 2012, pages 1-12.
Crossref
Crossref
Mine Ergüven & Ayhan Bilir. 2012. Midkine: From Embryogenesis to Pathogenesis and Therapy. Midkine: From Embryogenesis to Pathogenesis and Therapy
283
303
.
Christiane Sokollik, Abha Gupta & Simon C. Ling. 2012. Primary Liver Cancer. Primary Liver Cancer
143
160
.
Michael S. Samuel. 2012. Encyclopedia of Signaling Molecules. Encyclopedia of Signaling Molecules
1596
1601
.
Roman Perez-Soler, Yiyu Zou, Tianhong Li & Yi He Ling. (2011) The Phosphatase Inhibitor Menadione (Vitamin K3) Protects Cells from EGFR Inhibition by Erlotinib and Cetuximab. Clinical Cancer Research 17:21, pages 6766-6777.
Crossref
Crossref
Mi-Sook Kim. (2011) Future Cancer Therapy with Molecularly Targeted Therapeutics: Challenges and Strategies. Biomolecules and Therapeutics 19:4, pages 371-389.
Crossref
Crossref
Adam L. Garske, Ulf Peters, Arianna T. Cortesi, Jenny L. Perez & Kevan M. Shokat. (2011) Chemical genetic strategy for targeting protein kinases based on covalent complementarity. Proceedings of the National Academy of Sciences 108:37, pages 15046-15052.
Crossref
Crossref
Dominique Thabut, Chittaranjan Routray, Gwen Lomberk, Uday Shergill, Kevin Glaser, Robert Huebert, Leena Patel, Tetyana Masyuk, Boris Blechacz, Andrew Vercnocke, Erik Ritman, Richard Ehman, Raul Urrutia & Vijay Shah. (2011) Complementary vascular and matrix regulatory pathways underlie the beneficial mechanism of action of sorafenib in liver fibrosis. Hepatology 54:2, pages 573-585.
Crossref
Crossref
Razelle KurzrockSteven I. ShermanDouglas W. BallArlene A. ForastiereRoger B. CohenRanee MehraDavid G. PfisterEzra E.W. CohenLinda JanischForlisa NaulingDavid S. HongChaan S. NgLei YeRobert F. GagelJohn FryeThomas MüllerMark J. RatainRavi Salgia. (2011) Activity of XL184 (Cabozantinib), an Oral Tyrosine Kinase Inhibitor, in Patients With Medullary Thyroid Cancer. Journal of Clinical Oncology 29:19, pages 2660-2666.
Crossref
Crossref
Arti Yadav, Bhavna Kumar, Theodoros N. Teknos & Pawan Kumar. (2011) Sorafenib Enhances the Antitumor Effects of Chemoradiation Treatment by Downregulating ERCC-1 and XRCC-1 DNA Repair Proteins. Molecular Cancer Therapeutics 10:7, pages 1241-1251.
Crossref
Crossref
Lin-jiang Tong, Hua Xie, Ting Peng, Xiao-feng Liu, Xian-liang Xin, Xun Huang, Si-meng Chen, Hong-yan Liu, Hong-lin Li, Mei-yu Geng, Ming Yin & Jian Ding. (2011) Establishment of platform for screening insulin-like growth factor-1 receptor inhibitors and evaluation of novel inhibitors. Acta Pharmacologica Sinica 32:7, pages 930-938.
Crossref
Crossref
Davendra P. S. Sohal & Weijing Sun. (2011) Hepatocellular Carcinoma: Prevention and Therapy. Current Oncology Reports 13:3, pages 186-194.
Crossref
Crossref
Matthew A. J. Duncton. (2011) Minisci reactions: Versatile CH-functionalizations for medicinal chemists. MedChemComm 2:12, pages 1135.
Crossref
Crossref